252 related articles for article (PubMed ID: 32513667)
1. Optical coherence tomography-angiography for monitoring neovascularisations in macular telangiectasia type 2.
Tzaridis S; Hess K; Friedlander M; Holz FG
Br J Ophthalmol; 2021 May; 105(5):735-740. PubMed ID: 32513667
[TBL] [Abstract][Full Text] [Related]
2. Epiretinal Neovascularization: A Novel OCT Angiography Finding in Macular Telangiectasia Type 2.
Ayachit AG; Reddy LU; Joshi S; Ayachit GS
Ophthalmol Retina; 2019 Jun; 3(6):516-522. PubMed ID: 31174674
[TBL] [Abstract][Full Text] [Related]
3. Right-angled vessels in macular telangiectasia type 2.
Tzaridis S; Heeren T; Mai C; Thiele S; Holz FG; Charbel Issa P; Herrmann P
Br J Ophthalmol; 2021 Sep; 105(9):1289-1296. PubMed ID: 30808615
[TBL] [Abstract][Full Text] [Related]
4. PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
Christenbury JG; Phasukkijwatana N; Gilani F; Freund KB; Sadda S; Sarraf D
Retina; 2018 Jul; 38(7):1276-1288. PubMed ID: 28723848
[TBL] [Abstract][Full Text] [Related]
5. OCT of Outer Retinal Hyperreflectivity, Neovascularization, and Pigment in Macular Telangiectasia Type 2.
Krivosic V; Lavia C; Aubineau A; Tadayoni R; Gaudric A
Ophthalmol Retina; 2021 Jun; 5(6):562-570. PubMed ID: 32956858
[TBL] [Abstract][Full Text] [Related]
6. Spectral-Domain OCT Analysis of Risk Factors for Macular Atrophy Development in the HARBOR Study for Neovascular Age-Related Macular Degeneration.
Sadda SR; Abdelfattah NS; Lei J; Shi Y; Marion KM; Morgenthien E; Gune S; Balasubramanian S
Ophthalmology; 2020 Oct; 127(10):1360-1370. PubMed ID: 32402555
[TBL] [Abstract][Full Text] [Related]
7. Comparison of anatomical and visual outcomes following different anti-vascular endothelial growth factor treatments in subretinal neovascular membrane secondary to type 2 proliferative macular telangiectasia.
Karasu B; Gunay BO
Graefes Arch Clin Exp Ophthalmol; 2020 Jan; 258(1):99-106. PubMed ID: 31768680
[TBL] [Abstract][Full Text] [Related]
8. Incidence and phenotypical variation of outer retina-associated hyperreflectivity in macular telangiectasia type 2.
Mueller S; Gunnemann F; Rothaus K; Book M; Faatz H; Bird A; Pauleikhoff D
Br J Ophthalmol; 2021 Apr; 105(4):573-576. PubMed ID: 33414243
[TBL] [Abstract][Full Text] [Related]
9. Progression characteristics of ellipsoid zone loss in macular telangiectasia type 2.
Pauleikhoff D; Bonelli R; Dubis AM; Gunnemann F; Rothaus K; Charbel Issa P; Heeren TF; Peto T; Clemons TE; Chew EY; Bird AC; Sallo FB;
Acta Ophthalmol; 2019 Nov; 97(7):e998-e1005. PubMed ID: 30968592
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis of subretinal neovascularization associated with idiopathic juxtafoveal retinal telangiectasia - fluorescein angiography versus spectral-domain optical coherence tomography.
Chhablani J; Mithal K; Rao H; Narayanan R
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):549-53. PubMed ID: 24150706
[TBL] [Abstract][Full Text] [Related]
11. Progression of vascular changes in macular telangiectasia type 2: comparison between SD-OCT and OCT angiography.
Pauleikhoff D; Gunnemann F; Book M; Rothaus K
Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1381-1392. PubMed ID: 31093765
[TBL] [Abstract][Full Text] [Related]
12. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
[TBL] [Abstract][Full Text] [Related]
13. Are Dilated Fundus Examinations Needed for OCT-Guided Retreatment of Exudative Age-Related Macular Degeneration?
Patel Y; Miller DM; Fung AE; Hill LF; Rosenfeld PJ
Ophthalmol Retina; 2020 Feb; 4(2):141-147. PubMed ID: 31735634
[TBL] [Abstract][Full Text] [Related]
14. SWEPT SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF NEOVASCULAR MACULAR TELANGIECTASIA TYPE 2.
Zhang Q; Wang RK; Chen CL; Legarreta AD; Durbin MK; An L; Sharma U; Stetson PF; Legarreta JE; Roisman L; Gregori G; Rosenfeld PJ
Retina; 2015 Nov; 35(11):2285-99. PubMed ID: 26457402
[TBL] [Abstract][Full Text] [Related]
15. Macular Telangiectasia Type 1 Managed With Long-Term Aflibercept Therapy.
Kovach JL; Hess H; Rosenfeld PJ
Ophthalmic Surg Lasers Imaging Retina; 2016 Jun; 47(6):593-5. PubMed ID: 27327292
[TBL] [Abstract][Full Text] [Related]
16. Staging of macular telangiectasia: power-Doppler optical coherence tomography and macular pigment optical density.
Chin EK; Kim DY; Hunter AA; Pilli S; Wilson M; Zawadzki RJ; Werner JS; Park SS
Invest Ophthalmol Vis Sci; 2013 Jul; 54(7):4459-70. PubMed ID: 23716628
[TBL] [Abstract][Full Text] [Related]
17. FROM OUTER RETINAL NEOVACULARIZATION TO EXUDATIVE SUBRETINAL NEOVASCULARIZATION IN MACULAR TELANGIECTASIA TYPE 2.
Krivosic V; Zureik A; Tadayoni R; Gaudric A
Retina; 2024 Jul; 44(7):1217-1223. PubMed ID: 38900579
[TBL] [Abstract][Full Text] [Related]
18. Response to anti-vascular endothelial growth factor of abnormal retinal vascular net in para foveal telangiectasia group II images on optical coherence tomography-angiography.
Saoji K; Pathengay A; Chhablani J; Panchal B; Doshi S; Saldanha M
Indian J Ophthalmol; 2019 Jan; 67(1):105-108. PubMed ID: 30574903
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of anti-vascular endothelial growth factor therapy in subretinal neovascularization secondary to macular telangiectasia type 2.
Narayanan R; Chhablani J; Sinha M; Dave V; Tyagi M; Pappuru RR; Kuppermann BD
Retina; 2012; 32(10):2001-5. PubMed ID: 22990322
[TBL] [Abstract][Full Text] [Related]
20. Morphological characteristics preceding exudative neovascularisation secondary to macular telangiectasia type 2.
Hess K; Charbel Issa P; Holz FG; Tzaridis S
Br J Ophthalmol; 2022 Dec; 106(12):1736-1741. PubMed ID: 34167944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
